1. Maximizing oxaliplatin's impact on EGFR + colorectal cancer through targeted extracellular vesicles.
- Author
-
Chien, Shang-Tao, Huang, Yi-Jung, Huang, Ming-Yii, Fang, Yi-Ping, Chao, Shi-Wei, Li, Chia-Tse, Jhang, Wun-Ya, Hsu, Yun-Han, Wang, Shuo-Hung, and Chuang, Chih-Hung
- Abstract
Purpose: To investigate the ability of extracellular vesicles (EVs) to deliver oxaliplatin to epidermal growth factor receptor (EGFR
+ ) colorectal cancer cells and increase oxaliplatin's cytotoxicity. Method: Oxaliplatin was passively loaded into a stable cell line expressing cetuximab in membranes. EVs were collected and characterized for size, and their ability to target EGFR+ cells was tested. Cytotoxicity experiments were performed, and a xenograft cancer animal model was used to confirm the specific accumulation of oxaliplatin-loaded EVs with cetuximab-expressing membranes in EGFR+ cells. Results: EVs with cetuximab-expressing membranes were successfully produced and used to encapsulate oxaliplatin, resulting in consistently sized oxaliplatin-loaded EVs with cetuximab-expressing membranes. The oxaliplatin-loaded EVs with cetuximab-expressing membranes were specifically accumulated by EGFR+ cells, leading to significant cytotoxic effects on these cells. In the animal model, the oxaliplatin-loaded EVs with cetuximab-expressing membranes accumulated specifically in EGFR+ cells and significantly enhanced oxaliplatin's therapeutic efficacy against EGFR+ cancer cells. Conclusion: EVs with membrane-expressed bioactive molecules are a promising strategy for delivering therapeutic agents to EGFR+ colorectal cancer cells. Highlights: EVs with cetuximab-expressing membranes were used to encapsulate oxaliplatin and target EGFR+ cells. Oxaliplatin-loaded EVs with cetuximab-expressing membranes exhibited significant cytotoxic effects on EGFR+ cells. In a xenograft cancer animal model, oxaliplatin-loaded EVs with cetuximab-expressing membranes accumulated specifically in EGFR+ cells and significantly enhanced oxaliplatin's therapeutic efficacy against EGFR+ cancer cells. EVs with targeted membrane expression of drugs are a promising strategy for delivering therapeutic agents to specific cell populations. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF